Banque Cantonale Vaudoise Uni Qure N.V. Transaction History

Banque Cantonale Vaudoise

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$35.35 - $50.67 $412,888 - $591,825	-11,680 Closed	0 $0
Q3 2020 Oct 30, 2020	BUY	$35.98 - $47.66 $40,333 - $53,426	1,121 Added 10.62%	11,680 $430,000
Q2 2020 Jul 22, 2020	BUY	$45.06 - $67.74 $45,735 - $68,756	1,015 Added 10.63%	10,559 $476,000
Q1 2020 May 14, 2020	SELL	$40.01 - $73.97 $36,969 - $68,348	-924 Reduced 8.83%	9,544 $453,000
Q4 2019 Feb 10, 2020	BUY	$37.13 - $74.62 $388,676 - $781,122	10,468 New	10,468 $750,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

Stay updated on Banque Cantonale Vaudoise with notifications on news.